Effect of Empagliflozin on Podocyte Specific Proteins in African American Veterans With NDKD
Status:
Recruiting
Trial end date:
2026-12-01
Target enrollment:
Participant gender:
Summary
Primary Objective:To study podocyte specific injury markers in African American Veterans with
non-diabetic kidney disease(NDKD), on empagliflozin therapy.
Primary Endpoint: Assess the effect of Empagliflozin on podocyte-specific proteins in
exosomes isolated from subjects' urine, such as nephrin, podocalyxin and Wilms'Tumor (WT-1)
protein.
Secondary Objective:
1. Correlate changes in exosome-based podocyte specific proteins with standardized
biomarkers of kidney injury including urine albumin/creatinine ratio (ACR) and estimated
GFR.
2. Correlate systemic inflammatory markers (focusing on vascular and endothelial function)
that are already established such as interleukins (IL1, IL6, IL-12) , hs-CRP and
arterial stiffness measures with urine exosome-based podocyte protein estimation.
3. Correlate urine podocyte-specific protein markers with APOL1 mRNA expression levels in
blood mononuclear cells (MNC)